ERBB3 and cancer: Although patritumab has been shown to have limited activity, patritumab deruxtecan, an antibody–drug conjugate, has shown encouraging response rates in studies and trials for other HER3 positive cancers and is now being extended to HNSCC (24, 113, 116, 117).